Abbott has its hands in several areas of health care, which will come in handy if any one area stumbles. Specifically, its stent business is growing steadily as are sales of its nutritional products (think energy bars).
In April, Abbott snipped the ribbon on a $450 million, 330,000-square foot biotech plant in Puerto Rico, a signal that the company is trying to assert itself in new growth areas.
One bit of trouble to keep an eye on: Drug-coated stents by Abbott and other drug makers are currently in the news for potential blood clot risk they pose.
The real estate slowdown has made parts of the Sunbelt a lot more affordable. Fortune presents a guide to finding the best deals in five markets. (more) 
Is it possible for someone who doesn't run a hedge fund or win the lottery to retire at 50 (or so)? Yes. (more) 
